Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. Reply

N Engl J Med. 2024 Mar 21;390(12):1154-1155. doi: 10.1056/NEJMc2401126.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glomerulosclerosis, Focal Segmental* / drug therapy
  • Humans
  • Irbesartan / therapeutic use
  • Spiro Compounds*
  • Sulfonamides

Substances

  • Irbesartan
  • sparsentan
  • Spiro Compounds
  • Sulfonamides